0001104659-20-105312 Sample Contracts

WARRANT
Inhibikase Therapeutics, Inc. • September 15th, 2020 • Biological products, (no disgnostic substances) • Delaware

THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

AutoNDA by SimpleDocs
RESTATED AGREEMENT TO
Inhibikase Therapeutics, Inc. • September 15th, 2020 • Biological products, (no disgnostic substances) • Georgia

THE AGREEMENT TO REPAY AN INDIVIDUAL LOAN (the “Agreement”) that was initially entered into on the 5th of February, 2020 is RESTATED this 13th day of June, 2020 (the “Effective Date”), into by and between Inhibikase Therapeutics, Inc., a Delaware corporation (“Corporation”) and Milton H. Werner, Ph.D., individually a resident of the State of Georgia (“the Individual“).

AGREEMENT TO REPAY INDIVIDUAL LOAN
Inhibikase Therapeutics, Inc. • September 15th, 2020 • Biological products, (no disgnostic substances) • Georgia

THIS AGREEMENT TO REPAY AN INDIVIDUAL LOAN (the “Agreement”) is entered this 5th day of February, 2020 (the “Effective Date”), into by and between Inhibikase Therapeutics, Inc., a Delaware corporation (“Corporation”) and Milton H. Werner, Ph.D., individually a resident of the State of Georgia (“the Individual”).

LETTER AGREEMENT TO RESTATED AGREEMENT TO REPAY INDIVIDUAL LOAN
Letter Agreement • September 15th, 2020 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)

Reference is made to that certain Restated Agreement to Repay Individual Loan, dated June 13, 2020 (the “Agreement”), by and between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Corporation”) and Milton H. Werner, Ph.D. (the “Individual”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.

confidential
Consulting Agreement • September 15th, 2020 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • Georgia

THIS CONSULTING AGREEMENT (the "Agreement") is made and entered into as of the date indicated below (the "Effective Date") between Inhibikase Therapeutics, LLC, a Georgia limited liability company ("Company"), and Flagship Consulting, Inc. a Delaware corporation (the "Consultant"). Company and Consultant are sometimes collectively referred to in this Agreement as the "Parties."

WARRANT
Inhibikase Therapeutics, Inc. • September 15th, 2020 • Biological products, (no disgnostic substances) • Delaware

THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

Time is Money Join Law Insider Premium to draft better contracts faster.